(CercleFinance.com) – Sanofi gained nearly 0.6%, one of the biggest increases in the CAC40 of the day, while Oddo BHF announced this morning maintaining its ‘outperformance’ rating on the stock, with an objective unchanged price of 94 euros.
The analysis office recalls that Sanofi published this morning the results of its second phase 3 trial evaluating Dupixent in the treatment of chronic bronchitis (COPD).
The results of its trial are ‘positive and consistent’, and showed a 34% reduction in moderate to severe acute COPD exacerbations over a 52-week period.
‘The publication of these results comes almost 6 months before our expectations and should therefore reassure the market a little ahead of the R&D day scheduled for December 7,’ underlines the analyst.
Oddo BHF indicates that these clinical results confirm the group’s ambitions in the treatment of COPD and that the consensus already records adjusted sales of 1.5 billion euros in 2030 in this indication (1.8 billion euros unadjusted).
‘Upward revisions should be measured but the positive sentiment on the stock this morning was exacerbated after its Q3 profit warning. The group plans to submit a request for an indication extension before the end of the year in this indication, concludes the broker.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.